Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its earnings results on Tuesday. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01), Morningstar.com reports.
Shares of NASDAQ CYCC remained flat at $$0.48 during midday trading on Thursday. 62,406 shares of the stock were exchanged, compared to its average volume of 71,286. The stock has a market cap of $8.66 million, a P/E ratio of -0.77 and a beta of 2.98. Cyclacel Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $1.87. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.09 and a current ratio of 8.09. The firm’s fifty day moving average is $0.56.
Several equities research analysts recently commented on CYCC shares. Roth Capital reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Thursday, May 23rd. HC Wainwright reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, May 15th. Finally, Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.00.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Further Reading: Google Finance Portfolio Workaround
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.